Kadowaki, T, et al. – Researchers tried to find out the adequacy and safety of teneligliptin [a dipeptidyl peptidase–4 (DPP–4) inhibitor] added onto canagliflozin [an sodium glucose co–transporter 2 (SGLT2) inhibitor] monotherapy in Japanese patients with poorly controlled type 2 diabetes mellitus (T2DM) as part of the establishment of a fixed–dose combination of teneligliptin and canagliflozin. It was revealed that teneligliptin added onto ongoing canagliflozin enhanced glycaemic control and was well tolerated in Japanese patients with inadequately controlled T2DM.

Methods

• Japanese patients treated with canagliflozin (100 mg) for ≥12 weeks were assigned randomly to receive add–on teneligliptin (20 mg; C+T group) or placebo (C+P group) for 24 weeks.
• The preliminary outcome was the change in glycated haemoglobin (HbA1c) from baseline to Week 24.

Results

• It was noted that the between–group differences in reductions from baseline to Week 24 were significantly greater in the C+T group for HbA1c (–0.94%; p <0.001).
• They found similar incidence of adverse events in both groups (55.8% and 49.4% in the C+T and C+P groups, respectively).
• There were no episodes of hypoglycaemia.